Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call demonstrates a strong potential for growth with the anticipated rapid uptake of FILSPARI in FSGS, supported by existing payer access and high unmet needs. The management's confidence in broad coverage and high compliance rates for FILSPARI in IgAN further bolster this sentiment. Despite some lack of specific guidance on numbers, the overall outlook is positive with strong demand drivers and physician acceptance. The Q&A section reinforces the positive sentiment with a focus on education and alignment with treatment guidelines.
Key Financial Performance
Total U.S. Net Product Sales $124.5 million in the first quarter of 2026, reflecting strong year-over-year growth.
FILSPARI U.S. Net Product Sales $105.2 million in the first quarter of 2026, representing approximately 88% year-over-year growth. The growth was achieved despite typical beginning-of-year gross-to-net impact and fewer revenue recognition days.
Thiola and Thiola EC U.S. Net Product Sales $19.3 million in the first quarter of 2026.
License and Collaboration Revenue $2.7 million in the first quarter of 2026.
Total Revenue $127.2 million in the first quarter of 2026.
Research and Development (R&D) Expenses $57.1 million in the first quarter of 2026, compared to $46.9 million in the same period in 2025. The increase was primarily driven by the restart of enrollment in the Phase III HARMONY study of pegtibatinase.
Selling, General and Administrative (SG&A) Expenses $80.3 million in the first quarter of 2026, compared to $60.4 million in the same period in 2025. The increase was primarily due to investments in preparation for FILSPARI's launch in FSGS and investments in IgA nephropathy.
Royalty Expense $24.8 million in the first quarter of 2026, compared to $12.4 million in the same period in 2025. The increase was due to the Thiola intangible asset reaching the end of its accounting useful life and an increase in capitalized FILSPARI royalties.
Net Loss $37.1 million or $0.40 per basic share in the first quarter of 2026, compared to a net loss of $41.2 million or $0.47 per basic share in the same period in 2025.
Non-GAAP Adjusted Net Income $4.1 million or $0.05 per basic share in the first quarter of 2026, compared to a net loss of $16.9 million or $0.19 per basic share in the same period in 2025.
Cash, Cash Equivalents, Marketable Securities, and Receivables Approximately $352 million as of March 31, 2026. This includes a $25 million sales-based milestone payment from Mirum Pharmaceuticals recognized in Q4 2025 and received in April.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FDA approval for FILSPARI in FSGS: FILSPARI became the first and only approved medicine for FSGS, a rare kidney condition, marking a significant milestone for the company and expanding its indication to help over 30,000 patients in the U.S. without nephrotic syndrome.
FILSPARI in IgA nephropathy: Achieved record new patient start forms and is estimated to have a $3 billion potential peak sales opportunity across IgA nephropathy and FSGS.
Phase III HARMONY study of pegtibatinase: Enrollment restarted, with the first new patient dosed. The study aims to evaluate pegtibatinase for classical homocystinuria, targeting 7,000-10,000 patients globally. Top-line results are expected in the second half of 2027.
Market expansion for FILSPARI: FILSPARI is now approved for both IgA nephropathy and FSGS, with an estimated 100,000 eligible patients in the U.S. This represents a significant market opportunity.
Revenue growth: FILSPARI generated $105.2 million in revenue in Q1 2026, an 88% year-over-year increase, despite fewer revenue recognition days.
Commercial performance: Achieved record demand for FILSPARI with 993 new patient start forms in Q1 2026. Early adoption in FSGS is expected to be faster due to existing prescriber familiarity from IgA nephropathy.
Financial performance: Generated $124.5 million in total U.S. net product sales in Q1 2026, with strong year-over-year growth. Maintains a cash balance of $264.7 million as of March 31, 2026.
Strategic focus on rare diseases: The company is prioritizing growth in rare kidney diseases and advancing its pipeline, including the late-stage development of pegtibatinase for classical homocystinuria.
Long-term growth trajectory: FILSPARI's dual approval in IgA nephropathy and FSGS positions the company for sustained growth and leadership in rare kidney disease indications.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The transcript mentions forward-looking statements that involve known and unknown risks, uncertainties, and assumptions, which could cause actual results to differ materially. This highlights potential regulatory risks and uncertainties in achieving approvals or maintaining compliance.
Market Competition: There is a mention of new treatment options becoming available for IgA nephropathy, indicating competitive pressures in the market that could impact FILSPARI's market share and growth.
Supply Chain and Revenue Recognition: The transcript notes fewer revenue recognition days due to quarter-end timing and early week ordering patterns, which could impact financial reporting and cash flow.
Operational Costs: Increased R&D and SG&A expenses are highlighted, driven by the restart of the Phase III HARMONY study and investments in FILSPARI's launch. These rising costs could pressure profitability.
Economic and Financial Risks: The transcript mentions a net loss for the quarter despite revenue growth, indicating financial risks related to profitability and sustainability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
FILSPARI Revenue Potential: The company estimates that more than 100,000 patients in the U.S. could be eligible for FILSPARI, representing a $3 billion potential peak sales opportunity.
FSGS Market Opportunity: FILSPARI's approval for FSGS is expected to address more than 30,000 patients in the U.S., with the number anticipated to grow. Early adoption is expected to be faster compared to the IgAN launch.
HARMONY Study Timeline: The pivotal Phase III HARMONY study of pegtibatinase in classical homocystinuria is on track to deliver top-line results in the second half of 2027.
Pipeline Expansion: The company is advancing its pipeline, including the reinitiation of enrollment in the HARMONY study and the potential for pegtibatinase to become the first disease-modifying therapy for classical HCU.
Revenue Growth Outlook: FILSPARI's strong demand in IgA nephropathy and its recent approval in FSGS are expected to drive sustained revenue growth and long-term leadership in rare kidney disease indications.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you please characterize what you're seeing at this early stage of the FSGS launch and how it compares to the original IgAN rollout?
A:The FSGS launch is expected to have a faster uptake compared to the IgAN launch due to high unmet need, strong brand awareness, and existing payer access (97% pathway to access). The company is confident in a more rapid uptake and sees FSGS as a bigger opportunity than IgAN.
Q:How many FSGS PSFs have you recorded thus far in the launch? What proportion of early starts are coming through payer authorizations versus exceptions or appeals?
A:Management did not provide specific numbers, stating it is too early to quantify. However, they noted higher first-pass approval rates at the payer level compared to the IgAN launch.
Q:What is resonating with physicians in terms of the label and product profile for FSGS? Where do you think education is required?
A:Physicians have responded positively to the approval, but there is a need to educate them about the label, particularly regarding active nephrotic syndrome versus nephrotic range proteinuria. Awareness-building efforts are ongoing, especially among community nephrologists.
Q:Should we think about the uptake for FSGS similarly to the IgAN launch, which had 400-450 patient start forms in the first few quarters? Do you expect payers to cover secondary FSGS patients broadly despite the segment not being tested in Phase III?
A:Management did not provide guidance on PSF numbers but reiterated confidence in faster uptake for FSGS. Payers are not focused on FSGS subtypes and understand the progressive nature of the disease, which supports broad coverage.
Q:Do you think payers and physicians will focus on patients' history of nephrotic syndrome when prescribing FILSPARI?
A:Management does not believe this will be a limiting factor. They emphasized educating payers and physicians that nephrotic syndrome is a dynamic state and that FILSPARI is aligned with treatment guidelines for patients without active nephrotic syndrome.
Q:What are the discontinuation rates for FILSPARI in IgAN over time, and how does this compare to the IgAN Phase III trial?
A:Compliance and persistence rates for FILSPARI in IgAN are very high and consistent with the Phase III trial. Patients tend to stay on therapy due to positive reinforcement from reduced proteinuria and a consistent side effect profile.
Q:Can you provide some color on the conversion rate for patient start forms to patients starting treatment? Are there any reasons for drop-offs?
A:Conversion rates remain high with no significant drop-offs. Improvements in conversion have been made over time, and the team continues to perform well in translating PSFs into revenue.
Q:How does the competitive landscape for IgAN, including Novartis' Vanrafia, affect FILSPARI's positioning and demand drivers?
A:FILSPARI is positioned as a foundational nephroprotective treatment, replacing RAS inhibitors. The market is still developing, and most growth comes from expanding the market rather than competition. FILSPARI's unique positioning supports its continued growth.
Q:Are the early FSGS PSFs originating from existing FILSPARI IgAN prescribers or newly activated FSGS prescribers?
A:Both existing IgAN prescribers and newly activated FSGS prescribers are contributing to early PSFs. A halo effect is observed, with prescribers adopting FILSPARI for both indications.
Q:Where is FILSPARI being sequenced in FSGS treatment? Is it used in lieu of ACE/ARBs or alongside SGLT2s?
A:FILSPARI is used to replace RAS inhibitors (ACE/ARBs) and is initiated when patients are not in active nephrotic syndrome. SGLT2 inhibitors are used less frequently in FSGS due to limited data, but FILSPARI is seen as a superior option.
Q:What is the impact of shipping weeks on Q1 revenue for FILSPARI?
A:The company recognized approximately 12 weeks of revenue in Q1, which serves as a proxy for understanding the impact of shipping weeks.
Q:How confident are you that total homocysteine will remain an approvable endpoint for pegtibatinase in the Phase III trial?
A:The company is confident in total homocysteine as an approvable endpoint, as it was aligned with the FDA during discussions for the HARMONY study.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers for FSGS patient start forms (PSFs) and conversion rates, citing it was too early to quantify. They also did not provide guidance on PSF numbers for FSGS uptake or break out PSFs by indication. Additionally, they did not quantify the impact of shipping weeks on revenue beyond stating an average of 12 weeks of revenue recognition in Q1.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CJASN
COMPOSE study
FDA approval
FILSPARI beginning
FILSPARI syndrome
FSGS patient
FSGS population
FSGS syndrome
HCU pegtibatinase
II COMPOSE
IgAN
Nivi
Therapeutics Financial
Thiola
approval enthusiasm
asset
community patient
criterion
demand IgA
edema
efficacy safety
endpoint
enrollment study
expense royalty
gram day
homocysteine
launch FSGS
medicine IgA
nephropathy FSGS
patient study
presence
proteinuria gram
record
restart enrollment
royalty expense
royalty payment
sale milestone
serum albumin
shipment
shipping week
trajectory
type FSGS
TVTX Transcript
Travere Therapeutics, Inc. (TVTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Travere Therapeutics, Inc. (TVTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call demonstrates a strong potential for growth with the anticipated rapid uptake of FILSPARI in FSGS, supported by existing payer access and high unmet needs. The management's confidence in broad coverage and high compliance rates for FILSPARI in IgAN further bolster this sentiment. Despite some lack of specific guidance on numbers, the overall outlook is positive with strong demand drivers and physician acceptance. The Q&A section reinforces the positive sentiment with a focus on education and alignment with treatment guidelines.
Travere Therapeutics, Inc. (TVTX) Q4 2025 Earnings Call Transcript
Positive2-19
The earnings call highlights strong financial performance and strategic growth opportunities, particularly with FILSPARI's expanding market presence and potential FSGS approval. The Q&A section reinforced confidence in the company's strategies and market positioning, with positive insights on FILSPARI's growth potential and FDA interactions. Despite some uncertainties in FDA requests and specific metrics, the overall sentiment remains positive due to robust market opportunities and strategic plans.
TVTX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
